Structural analyses ofCandida albicanssterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds

(2016) W. A. Schell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cell biology of Candida albicans –host interactions

(2016) Alessandra da Silva Dantas et al.   CURRENT OPINION IN MICROBIOLOGY

Candidemia and invasive candidiasis in adults: A narrative review

(2016) Spinello Antinori et al.   European Journal of Internal Medicine

How can we bolster the antifungal drug discovery pipeline?

(2016) Josef Jampilek   Future Medicinal Chemistry

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience

(2016) Wirawan Jeong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design

(2016) Tatiana Y. Hargrove et al.   JOURNAL OF LIPID RESEARCH

The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen

(2016) Joachim Morschhäuser   JOURNAL OF MICROBIOLOGY

Candida albicans cell-type switching and functional plasticity in the mammalian host

(2016) Suzanne M. Noble et al.   NATURE REVIEWS MICROBIOLOGY

Role of isavuconazole in the treatment of invasive fungal infections

(2016) Dustin Wilson et al.   Therapeutics and Clinical Risk Management

Clinical Candidate VT-1161's Antiparasitic EffectIn Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi

(2015) William J. Hoekstra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis

(2015) E. P. Garvey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2015) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) fromAspergillus fumigatusand Molecular Basis for the Development of Antifungal Drugs

(2015) Tatiana Y. Hargrove et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis

(2015) Galina I. Lepesheva et al.   JOURNAL OF INFECTIOUS DISEASES

Molecular mechanisms associated with Fluconazole resistance in clinicalCandida albicansisolates from India

(2015) Arati Mane et al.   MYCOSES

Invasive Candidiasis

(2015) Bart Jan Kullberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

How to bolster the antifungal pipeline

(2015) D. W. Denning et al.   SCIENCE

Design and optimization of highly-selective fungal CYP51 inhibitors

(2014) William J. Hoekstra et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Sequence variation in CYP51A from the Y strain ofTrypanosoma cruzialters its sensitivity to inhibition

(2014) Tatiana S. Cherkesova et al.   FEBS LETTERS

Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition

(2014) Laura Friggeri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Epidemiology and risk factors for invasive candidiasis

(2014) Nur Yapar   Therapeutics and Clinical Risk Management

Complexes ofTrypanosoma cruziSterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

(2013) Tatiana Y. Hargrove et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite Growth

(2013) Grasiella Andriani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen

(2012) Iuliana V. Ene et al.   CELLULAR MICROBIOLOGY

Hidden Killers: Human Fungal Infections

(2012) G. D. Brown et al.   Science Translational Medicine

Triazole Antifungal Agents in Invasive Fungal Infections

(2011) Cornelia Lass-Flörl   DRUGS

Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) fromLeishmania infantum

(2011) Tatiana Y. Hargrove et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol

(2011) Tatiana Y. Hargrove et al.   JOURNAL OF LIPID RESEARCH

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Structural basis for conservation in the CYP51 family

(2010) Galina I. Lepesheva et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature

(2010) Florent Morio et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human PathogenTrypanosoma cruzi

(2010) Galina I. Lepesheva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections

(2009) Galina I. Lepesheva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY